Background
==========

Many murine leukemia viruses (MLVs) belonging to the genus gammaretroviruses induce cancer when injected into susceptible newborn mice \[[@B1],[@B2]\]. These simple retroviruses do not themselves harbor transduced oncogenes, and their ability to cause cancer relies on the host cellular genes that are transcriptionally activated or otherwise mutated as a result of the integrated provirus \[[@B3]-[@B6]\].

Regarding the virus itself, it is well documented that the LTR region plays a crucial role for both the strength and cell type specificity of disease induction \[[@B7],[@B8]\]. Within the LTR the specificity has been located mainly to the enhancer region in U3, and further narrowed down to the sequences defining different transcription factor binding sites \[[@B9]-[@B12]\]. In spite of this predominant role of the LTR in MLV pathogenesis, also sequences outside this region have been shown to be important for the ability and potency of a particular virus to induce cancer. Infection is mediated by interaction between the viral envelope protein (Env) and a specific host cell receptor, and for the ecotropic MLVs such as Moloney, Akv, and SL3-3, this receptor has been identified as the mouse cationic amino acid transporter 1 (mCAT1) \[[@B13],[@B14]\]. A significant role of *env*in MLV pathogenesis is the involvement in the generation of recombinant polytropic viruses that takes place during T-cell lymphoma development. These MCF (mink cell focus-forming) viruses have the ability to superinfect cells, an aspect which is thought to contribute to tumor formation \[[@B15],[@B16]\]. In addition to the *env*gene, and perhaps somewhat surprisingly, the viral *gag*gene sequences have also proven to play a role in MLV pathogenesis. Thus, Audit *et al*. (1999) \[[@B17]\] showed that the introduction of only three synonymous nucleotide mutations in the capsid-coding gene of Moloney MLV (Mo-MLV) changed the oncogenic properties of this virus. The mutations were located at an alternative splice donor site (SD\'), which together with the canonical *env*splice acceptor site was shown to produce a subgenomic transcript of 4.4 kb \[[@B18]\]. The equivalent transcript, produced by Friend MLV, was subsequently shown to be packaged into virions, reversely transcribed and integrated in the host genome by normal viral mechanisms \[[@B19]\]. While wild-type Mo-MLV induces T-cell lymphomas in 100% of the inoculated mice, the SD\' mutant virus exhibited a much broader specificity, thus inducing -- besides the expected T-cell tumors -- erythroid or myelomonocytic leukemias. In contrast, the corresponding mutations in a Friend MLV background did not seem to influence the pathogenic potential of this virus at all. Both wild-type and mutant Friend MLVs induced exclusively the characteristic erythroleukemia \[[@B17]\]. So it seems that the importance for the disease-inducing potential of the SD\' site, although conserved among many species, is strongly dependent on the virus type.

The SD\' site has also been found to be used for production of the oncogenic *gag-myb*fusion RNAs in promonocytic leukemias induced by Mo-MLV in pristane-treated BALB/c mice \[[@B20]\]. When the SD\' site was mutated in this model, the overall disease incidence was not affected; however the proportion of myeloid leukemia decreased significantly, while the proportion of lymphoid leukemia increased. Moreover, no 5\' insertional activation of c-*myb*(using alternative splice donor sites) could be found, thereby signifying a specific requirement of the SD\' site for this mechanism \[[@B21]\].

Here we report of the identification of an alternative splice acceptor site, SA\', located in the capsid region of *gag*, which together with the *gag*splice donor site, SD\' (corresponding to the one reported for Moloney and Friend MLV), or together with a second alternative *gag*splice donor site, SD\*, defines a novel exon within the genus gammaretroviruses. We show that RNA splicing by use of the alternative splice sites does indeed take place in tumor tissue, and that both double- and single-spliced transcripts are produced. When mutating the SD\', the SA\', or both sites simultaneously, the splicing pattern is affected in a predictable way. Moreover, we demonstrate that the SA\' and SD\' mutations alter the oncogenic specificity of the Akv MLV, displayed by a change in the distribution of the diagnoses of the resulting tumors as well as by an induction of tumors of altered specificity such as histiocytic sarcoma and *de novo*diffuse large B cell lymphoma (DLBCL).

Results
=======

Identification of a novel exon residing within the *gag*region of Akv MLV
-------------------------------------------------------------------------

In order to identify potential alternative splice donor and splice acceptor sites in Akv MLV, exon-trapping was performed using the exon-trapping vector pSPL3 (see Materials and Methods). In short, an exon resulting from usage of the alternative splice acceptor (SA\') and either one of two alternative splice donor (SD\' or SD\*) sites located in the capsid region of *gag*(Fig. [1](#F1){ref-type="fig"}), was isolated and verified by RT-PCR analyses of RNA isolated from Akv MLV infected cells (data not shown). The size of the exon is 235 bp or 180 bp, depending on the splice donor site used.

![Location of the trapped exon. Upper panel shows the structure of proviral Akv MLV DNA with the positions of the splice sites indicated (SD; splice donor, SA; splice acceptor). Arrows signify the PCR primers used to verify the stability of the introduced mutations. Lower panel shows the positions and types of the introduced mutations, marked by asterisks and underlined. The SA\'/SD\'-delineated exon is indicated by the box. The boldfaced A in the sequence indicates the presumed branch point.](1742-4690-4-46-1){#F1}

Mutations of the alternative splice sites affect the specificity of the induced tumors
--------------------------------------------------------------------------------------

To analyze a possible effect *in vivo*of the novel exon, defined by SA\' and SD\', three different alternative splice site mutant viruses, Akv-CD, Akv-EH, and Akv-CDH, mutated in either the SA\' or SD\' site, or in both sites simultaneously, were constructed and injected into newborn mice of the inbred NMRI strain. Fig. [1](#F1){ref-type="fig"} shows the precise locations of the synonymous mutations around the trapped exon. Without altering the coding potential of the capsid gene, the mutations affect the branch point site, the pyrimidine region, the conserved splice junction AG and GT dinucleotides, and the fairly well-conserved exonal A at the SD\' junction site. The positions of the three intron mutations at the SD\' junction site are identical to those in Moloney and Friend MLV described by Audit et al. (1999) \[[@B17]\].

As can be seen from Fig. [2](#F2){ref-type="fig"} and Table [1](#T1){ref-type="table"} the majority of the infected mice (about 90%) developed tumors within 250 days with similar average latency periods of about 200 days for the four types of virus. Histological examination (examples shown in Fig. [3](#F3){ref-type="fig"}) and diagnosis according to the Bethesda classification \[[@B22]\] revealed that a large proportion (approx. 70%) of the total numbers of tumors could be classified as either follicular B-cell lymphoma (FBL) (13%), diffuse large B-cell lymphoma (DLBCL) progressed from FBL (33%), or plasmacytoma (PCT) (25%) (Table [2](#T2){ref-type="table"}). However, the distribution was quite different within the different virus series; thus, almost one quarter of the Akv-wt induced tumors were diagnosed as FBL, while no tumor of the Akv-CD group (p \< 0.05) or one tumor each of the Akv-EH or Akv-CDH groups fell into this group. In contrast, within the DLBCL tumors progressed from FBL the frequencies are similar (ranging from 24% to 39%) no matter if the causative virus contained mutated SA\' and/or SD\' sites or not. In the PCT group it appears that mutating the SA\' site significantly impaired the ability of the virus to induce PCT (p \< 0.05). On the other hand, this effect was not statistically significant if the SD\' site was mutated, and curiously if both sites were mutated, wild-type level for PCT induction was restored.

###### 

Disease latency and frequency

  **Virus**     **Average latency period (days)**   **Frequency of mice developing hematopoitic tumors**
  ------------- ----------------------------------- ------------------------------------------------------
  **Akv-wt**    184 ± 26                            40/40
  **Akv-CD**    201 ± 30                            17/19
  **Akv-EH**    184 ± 34                            17/18
  **Akv-CDH**   190 ± 46                            14/16

###### 

Frequency and latency of induced tumors

  **Virus**                       **FBL**       **DLBCL (progression from FBL)**   ***De novo*DLBCL\#**   **PCT**       **SMZL**     **DLBCL (progression from SMZL)**   **SBL**     **PTLL**    **STL**     **Histiocytic sarcoma**
  ------------------------------- ------------- ---------------------------------- ---------------------- ------------- ------------ ----------------------------------- ----------- ----------- ----------- -------------------------
  **Akv-wt**                      9/40 (23%)    13/40 (33%)                        0/40 (0%)              13/40 (33%)   3/40 (8%)    0/40 (0%)                           2/40 (5%)   0/40 (0%)   0/40 (0%)   0/40 (0%)
  **Akv-CD\***                    0/18 (0%)     7/18 (39%)                         0/18 (0%)              1/18 (6%)     5/18 (28%)   1/18 (6%)                           0/18 (0%)   0/18 (0%)   0/18 (0%)   4/18 (22%)
  **Akv-EH**                      1/17 (6%)     4/17 (24%)                         6/17 (35%)             3/17 (18%)    0/17 (0%)    1/17 (6%)                           0/17 (0%)   0/17 (0%)   1/17 (6%)   0/17 (0%)
  **Akv-CDH**                     1/14 (7%)     5/14 (36%)                         0/14 (0%)              5/14 (36%)    0/14 (0%)    0/14 (0%)                           0/14 (0%)   1/14 (7%)   0/14 (0%)   0/14 (0%)
                                                                                                                                                                                                             
  **Total**                       11/88 (13%)   29/88 (33%)                        6/88 (7%)              22/88 (25%)   8/88 (9%)    2/88 (2%)                           2/88 (2%)   1/88 (1%)   1/88 (1%)   4/88 (5%)
  **Av. latency period (days)**   188 ± 30      198 ± 31                           187 ± 43               180 ± 27      207 ± 20     174 ± 18                            153 ± 12    107         146         211 ± 36

Abbreviations: FBL, follicular B cell lymphoma; DLBCL, diffuse large B cell lymphoma; PCT, plasmacytoma; SMZL, splenic marginal zone lymphoma; SBL, small B cell lymphoma; PTLL, precursor T cell lymphoblastic lymphoma; STL, small T-cell lymphoma.

\# *De novo*DLBCL refers to Bethesda classification \"DLBCL centroblastic\"; however, to stress the parallel to human *de novo*lymphomas we use this term.

\*In this group one of the 17 mice that developed tumors had two tumors, hence a total number of 18 tumors.

![Pathogenicity of Akv and derived splice site mutants in inbred NMRI mice. Shown are the cumulative incidences of tumor development related to age of injected mice (in days).](1742-4690-4-46-2){#F2}

![Histopathology of tumors induced by Akv and derived splice site mutants. Representative examples are shown. (A to D) *de novo*diffuse large B-cell lymphoma. (A) Low magnification of a spleen infiltrated by a vaguely nodular lymphoid neoplasia (H&E staining). Magnification, ×25. (B) Higher magnification demonstrates that the neoplasia is composed of a monotonous population of large cells with blastic chromatin, one to three nucleoli and abundant eosinophilic cytoplasm characteristic of centroblasts (H&E staining). Magnification, ×640. (C) Anti-B220 highlights the large neoplastic cells, which are strongly positive (immunohistochemistry). Magnification, ×400. (D) Anti-CD3 shows that only few residual reactive T-cells are present (immunohistochemistry). Magnification, ×400. (E to H) Follicular lymphoma. (E) Low magnification of a spleen infiltrated by a clear nodular lymphoid proliferation (H&E staining). Magnification, ×25 (F) Higher magnification shows a combination of large centroblasts intermingled with small- to medium-sized lymphocytes or centrocytes (H&E staining). Magnification, ×640. (G) Anti-B220 highlights the expansion of the follicles, mainly of the germinal center lymphoid cells (light brown) (immunohistochemistry). Magnification, ×25. (H) Anti-CD3 reveals the presence of abundant reactive T-cells intermingled with the neoplastic B-cells (immunohistochemistry). Magnification, ×400. (I to L) Marginal zone cell lymphoma. (I) Low magnification of a spleen infiltrated by a marginal zone lymphoma. Note that the follicles (F) are small and the cells surrounding these follicles expand and infiltrate the red pulp in a marginal zone pattern (H&E staining). Magnification, ×100. (J) Higher magnification showing that the neoplasia is composed of a monotonous population of small- to medium-sized cells with open fine chromatin, inconspicuous nucleoli and abundant light eosinophilic cytoplasm (H&E staining). Magnification, ×400. (K) Anti-CD79a reveals that the tumor cells in the marginal zone area are strongly positive, whereas the cells in the germinal centers (F) are weakly positive. The opposite staining pattern is seen with anti-B220 (data not shown) (immunohistochemistry). Magnification, ×200. (L) Higher magnification with anti-CD79a shows a uniform membranous positivity of the tumor cells (immunohistochemistry). Magnification, ×400. (M to O) Histiocytic sarcoma. (M) Low magnification of a spleen diffusely infiltrated by a histiocytic sarcoma (H&E staining). Magnification, ×25. (N) Higher magnification shows the presence of large cells with abundant eosinophilic cytoplasm and bland nuclei characteristic of histiocytes (H&E staining). Magnification, ×400. (O) Anti-Mac 3 shows that all tumor cells are positive for this histiocytic marker, both in the cytoplasm and in the cell membrane (immunohistochemistry). Magnification, ×4 Histopathological and immunohistological analyses of tumor tissues.](1742-4690-4-46-3){#F3}

In line with this, the most dramatic effect in general was seen when only the SA\' site was mutated as shown for Akv-CD; the tumor incidence of this mutant with respect to splenic marginal zone lymphoma (SMZL) increased from 8% to 28% (p \< 0.1) and decreased to 0% as shown for Akv-EH (p \< 0.05) and for Akv-CDH (p = 0.5). Moreover, the Akv-CD mutant virus was the only one that displayed a capability for inducing histiocytic sarcoma, a tumor type which has not been observed in any of our previous studies using NMRI mice (inbred or random-bred) infected with Akv, SL3-3, or different derived mutants of these. So in brief, synonymous mutations at the SA\' site of Akv MLV markedly altered the oncogenic potential of the virus by significantly impairing the ability to induce both FBL and PCT. Besides, while the development of SMZL was increased by Akv-CD, it was abolished in Akv-EH and Akv-CDH, and most notably, a novel potential for inducing histiocytic sarcoma was established.

The most pronounced effect of mutating the SD\' site (Akv-EH) is the frequent occurrence (35%) of diffuse tumors, which according to the Bethesda classification represent DLBCL centroblastic (more than 50% of the infiltrating population is centroblasts). These tumors, where progression is not from either a follicular or a marginal lymphoma, are comparable to the *de novo*lymphomas in humans, and to emphasize this association we have used the term *de novo*DLBCL (Table [2](#T2){ref-type="table"}). Strikingly, *de novo*DLBCLs were never observed among the wild-type induced tumors or among the other mutant induced tumors (p \< 0.05). The finding of such tumors in mice is rare and could be exploited to understand the molecular changes in *de novo*DLBCL of mice, and eventually a useful mouse model of human *de novo*DLBCL might be generated from this set-up.

Quite unexpectedly, the effect of mutating the SA\' and SD\' sites simultaneously (Akv-CDH) was the less manifested one. FBL incidence dropped from 23% to 7%; otherwise this mutant in our experimental setting displayed similar tumorigenic potential as the wild-type Akv MLV.

Conservation of the introduced splice site mutations in the tumors
------------------------------------------------------------------

To determine the stability of the introduced mutations, the regions containing the mutations were PCR amplified from genomic DNA prepared from the induced tumors, using the primers depicted in Fig. [1](#F1){ref-type="fig"}. The sequences of the amplified fragments confirmed in all cases the integrity of the introduced mutations (data not shown).

Both single- and double-spliced transcripts are generated *in vivo*
-------------------------------------------------------------------

The observed effect of the mutated splice sites on the oncogenic properties advocates that RNA splicing by means of the alternative SA\' and SD\' sites does indeed take place *in vivo*. To clarify and confirm the identity of the produced transcripts, the splice pattern in tumor tissues (and for comparison in NIH 3T3 cells infected with the same four viruses) was analyzed. RNA from the individual end-stage tumors (or from virally infected cells) was isolated, and conventional RT-PCRs were performed with primers designed in such a way that it should be possible to identify all four potential splice products using 4 different primer sets as shown in Fig. [4A](#F4){ref-type="fig"}.

![RT-PCR analyses of splice products generated *in vivo*. (A) The structures of the potential splice products A to D are illustrated at the top, with the positions and orientations of the PCR primers (see Materials and Methods) from the four primer sets depicted below. The predicted origins and sizes of the amplified fragments are given at the right. (B) Shown are examples from each series of amplified RT-PCR products visualized on ethidium bromide-stained agarose gels. The employed primer sets (\#1 to \#4) are listed above the lanes. Size markers are indicated at the left.](1742-4690-4-46-4){#F4}

With a few exceptions, all tumors were analyzed, and sequences of the amplified RT-PCR products determined to validate the specificity of the fragments (data not shown). Representative results from each virus series are shown in Fig. [4B](#F4){ref-type="fig"}. In all cases, PCR products representing splice product A (the regular *env*transcript; primer set \#4) was observed, which implies that damage of the alternative splice sites, SA\' and SD\', does not impair the production of the regular single-spliced *env*RNA. Concerning splice product D (primer set \#1) it was never amplified, neither from tumor tissues nor from cell culture studies, strongly indicating that this is not a *bona fide*transcript. The lack of detection of product D is unlikely to result from a technical PCR-problem since the two primers have been validated in other PCRs.

For the Akv wild-type induced tumors, RT-PCR products representing the double-spliced product B (primer set \#2), and fragments of expected size amplified by primer set \#3, indicative of splice product B or C, were observed in all cases. As would be expected primer set \#2, which is dependent on an intact SA\' site, did not result in any amplification products using RNA from Akv-CD or Akv-CDH tumors. Surprisingly however, in five out of 14 analyzed Akv-EH tumor samples (represented by Akv-EH tumor no. 14 in Fig. [4B](#F4){ref-type="fig"}), a product slightly smaller than that of transcript version B was amplified. The subsequent sequence analyses revealed that the alternative splice donor site SD\* (depicted in Fig. [1](#F1){ref-type="fig"}) in these cases consistently had been used, resulting in the generation of a splice product equivalent in structure to product B, however 54 nucleotides shorter. No correlation between tumor cell specificity and usage of the SD\* site could be observed, since the five tumor samples originated from FBL, DLBCL progressed from FBL, *de novo*DLBCL, and the single case of STL (small T-cell lymphoma). The presence of the same splice product from the SD\* site was verified by sequence analysis of RT-PCR products derived from tumors induced by the wild-type virus in some cases, although the product was consistently less prominent than product B.

Transcript C corresponds to the single-spliced transcript of 4.4 kb, which previously has been reported to be produced by both Friend and Moloney MLV using the SD\' together with the canonical *env*SA\' site \[[@B18],[@B19]\]. Our RT-PCR results confirm the existence of this single-spliced transcript, since products of the expected size were always amplified with primer set \#3 using RNA from Akv-CD tumors (Fig. [4B](#F4){ref-type="fig"}), whereas product B (primer set \#2) was never amplified in this material.

In summary, by means of the alternative splice sites that define the novel *gag*exon, both a single-spliced transcript C as well as a novel double-spliced transcript B is produced *in vivo*, and when these alternative splice sites are destroyed, the splicing pattern is changed concordantly.

The same RT-PCR analyses were performed for NIH 3T3 cells infected with the four viruses, which led to the same splice pattern (data not shown). In addition, Northern blot hybridizations with an ecotropic *env*-probe and with a probe covering the novel SA\'-SD\' defined exon in *gag*were performed with RNA isolated from these cells (Fig. [5](#F5){ref-type="fig"}). Besides the expected hybridization patterns of prominent bands of full-length (*env*and *gag*probe) and *env*mRNA (only *env*probe) sizes, a weaker band of a size corresponding to splice product C (4.4 kb) was detected with both probes. No distinct band corresponding to spliced RNA B was observed, suggesting a very low level of production and/or significant messenger instability.

![Northern blot hybridizations with an ecotropic specific *env*probe and a *gag*probe of RNA isolated from NIH 3T3 cells chronically infected with the viruses listed above each lane. The sizes of the full-length transcript (unspliced) and the single-spliced *env*transcript are indicated at the left. The arrow indicates splice product C. For verification of integrity and concentration of the loaded RNA, the original ethidium bromide stained agarose gel exposing 18S and 28S rRNAs is shown below.](1742-4690-4-46-5){#F5}

Provirus integration site analyses
----------------------------------

In order to identify a possible connection between specific retroviral integration sites (RIS) and specific diagnostic tumor types, provirus integration sites from the majority of the induced tumors were isolated and sequenced. We have then by subsequent homology searches of the mouse genome databases identified 240 unambiguous integration sites (Table [3](#T3){ref-type="table"}). These integration site sequences represent tumors from 30 out of 40 (104 sequences), 14 out of 19 (46 sequences), 14 out of 18 (51 sequences), and 11 out of 16 (39 sequences) mice infected by Akv-wt, Akv-CD, Akv-EH, and Akv-CDH, respectively. This corresponds to an average of 3.6 integrations per analyzed tumor. Based on the searches in the UCSC database \[[@B23]\], and the Mouse Retrovirus Tagged Cancer Gene Database, RTCGD \[[@B24],[@B25]\], both version mm8, 111 novel RISs were identified. In an attempt to pick up candidate cancer genes that might be associated with specific tumor diagnoses, we looked for common integration sites (CISs), which would infer such genes \[[@B25],[@B26]\]. Hence, we compared the integration sites with each other as well as with previously defined RISs in RTCGD. In principle, using the recommendations from RTCGD with a window size of 100 kb, 50 kb, and 30 kb for CISs with 4 (or more), 3, or 2 insertions, respectively, we were hereby able to define 35 novel common integration sites (CISs) (Table [3](#T3){ref-type="table"}). Just a single one of these could be correlated with a specific diagnosis and with a specific virus, since in two independently Akv-wt induced plasmacytomas a definite region of chromosome 15 was targeted. However, this region does not contain genes/RefSeqs within a 100 kb distance from the integrated proviruses, so for the present we cannot predict what -- if any -- candidate gene(s) that might have been influenced by the integrated proviruses. For the remaining 34 CISs more than one virus and more than one tumor diagnosis were implicated, which implies that no straightforward association between target gene (and/or causative virus) and tumor type can be deduced.

###### 

Positions of integrated proviruses in tumor DNA

  **\#**   **Virus**   **Diagnosis**         **Chromosome**   **Position (mm8)**   **Gene/RefSeq^a^**   **No. of hits in RTCGD (mm8)**   **Novel RISs^b^**   **Novel CISs^c^**
  -------- ----------- --------------------- ---------------- -------------------- -------------------- -------------------------------- ------------------- -------------------
  1        Akv-EH      DLBCL (from FBL)      1                24641886             Lmbrd1               0                                1                   \-
  2        Akv-EH      DLBCL (from FBL)      1                36406157             Cnnm4                0                                1                   \-
  3        Akv wt      DLBCL (from FBL)      1                78743292             Kcne4                0                                1                   \-
  4        Akv-EH      PCT                   1                82855932             Slc19a3              0                                1                   \-
  5        Akv wt      FBL                   1                93014894             Ramp1                5                                \-                  \-
  6        Akv-CD      *n.d.*                1                93022552                                                                                       
  7        Akv-EH      Lymphoma, NOS         1                120226476            AK080782             0                                1                   \-
  8        Akv-CD      DLBCL (from FBL)      1                130341056            Cxcr4                3                                \-                  \-
  9        Akv wt      PCT                   1                135878316            Fmod/Btg2            8                                \-                  \-
  10       Akv wt      DLBCL (from FBL)      1                135882183                                                                                      
  11       Akv-CD      Abscess               1                139604557            \-\--                1                                \-                  1
  12       Akv wt      PCT                   1                144940508            \-\--                0                                1                   \-
  13       Akv wt      PCT                   1                163725782            AK029097             0                                1                   \-
  14       Akv wt      FBL                   1                173476364            Slamf7               0                                1                   \-
  15       Akv wt      PCT                   1                174350588            Tagln2/AK006449      2                                \-                  \-
  16       Akv wt      DLBCL (from FBL)      1                182219328            MGC68323/AK038867    2                                \-                  \-
  17       Akv-CD      SMZL                  2                11542293             Il2ra                4                                \-                  \-
  18       Akv-CDH     DLBCL (from FBL)      2                13133178             Rsu1                 0                                1                   \-
  19       Akv-CDH     PCT                   2                35270244             Ggta1                5                                \-                  \-
  20       Akv wt      DLBCL (from FBL)      2                44741201             Gtdc1                0                                1                   \-
  21       Akv wt      DLBCL (from FBL)      2                46263959             \-\--                0                                1                   \-
  22       Akv wt      DLBCL (from FBL)      2                71667822             Itga6/Pdk1           0                                1                   \-
  23       Akv wt      DLBCL (from FBL)      2                90883313             Slc39a13/Sfpi1       6                                \-                  \-
  24       Akv wt      SMZL                  2                90883476                                                                                       
  25       Akv wt      PCT                   2                102668507            Cd44                 0                                1                   \-
  26       Akv wt      DLBCL (from FBL)      2                102782324            Pdhx                 0                                1                   \-
  27       Akv wt      FBL                   2                118352393            Pak6                 0                                1                   \-
  28       Akv wt      FBL                   2                119028536            Spint1               0                                1                   \-
  29       Akv-CDH     Lymphoma, NOS         2                120301032            Zfp106               1                                \-                  1\*
  30       Akv-CDH     PTLL                  2                128875013            Slc20a1              0                                1                   \-
  31       Akv-CDH     Lymphoma, NOS         2                129283153            Ptpns1               1                                \-                  1
  32       Akv-EH      PCT                   2                131711284            Rassf2               0                                1                   \-
  33       Akv-CDH     DLBCL (from FBL)      2                158379688            Ppp1r16b             4                                \-                  \-
  34       Akv wt      SMZL                  2                164051325            Slpi                 0                                1                   \-
  35       Akv wt      DLBCL (from FBL)      2                169860192            Zfp217               5                                \-                  \-
  36       Akv wt      FBL                   3                22265638             Tbl1xr1              0                                1                   \-
  37       Akv-CDH     PCT                   3                27464311             Aadacl1              0                                1                   \-
  38       Akv-CDH     DLBCL (from FBL)      3                30203814             Evi1                 5                                \-                  \-
  39       Akv-CDH     PCT                   3                30203870                                                                                       
  40       Akv-CDH     Lymphoma, NOS         3                76043446             Golph4               0                                1                   \-
  41       Akv-EH      DLBCL (from FBL)      3                79339620             \-\--                0                                1                   \-
  42       Akv wt      FBL                   3                90334704             Slc39a1              0                                1                   \-
  43       Akv-CD      DLBCL (from FBL)      3                96900321             Cd160                0                                1                   \-
  44       Akv wt      SMZL                  3                98031475             LOC433632            13                               \-                  \-
  45       Akv-EH      PCT                   3                98041399                                                                                       
  46       Akv-CD      SMZL                  3                98043109                                                                                       
  47       Akv-CDH     DLBCL (from FBL)      3                98043150                                                                                       
  48       Akv wt      PCT                   3                98043377                                                                                       
  49       Akv wt      DLBCL (from FBL)      3                98043659                                                                                       
  50       Akv-CD      SMZL                  3                98064421                                                                                       
  51       Akv-CDH     DLBCL (from FBL)      3                98127957             Notch2               8                                \-                  \-
  52       Akv-EH      PCT                   3                108214198            Ampd2                0                                1                   \-
  53       Akv-CD      SMZL                  3                115828351            Dph5                 1                                \-                  1
  54       Akv wt      DLBCL (from FBL)      3                131582947            Papss1               1                                \-                  \-
  55       Akv wt      SBL                   3                145870070            Bcl10                3                                \-                  \-
  56       Akv wt      DLBCL (from FBL)      3                146091393            Mcoln2               0                                1                   \-
  57       Akv-EH      DLBCL (from FBL)      3                157996860            Lrrc40               0                                1                   \-
  58       Akv wt      SBL                   4                8842182              BC034239             1                                \-                  1
  59       Akv-CDH     PCT                   4                11915327             AK132816             0                                1                   \-
  60       Akv-CD      DLBCL (from FBL)      4                32560128             Bach2                14                               \-                  \-
  61       Akv wt      FBL                   4                32611866                                                                                       
  62       Akv-CD      *n.d.*                4                32619341                                                                                       
  63       Akv wt      PCT                   4                32702311                                                                                       
  64       Akv-CD      Histiocytic sarcoma   4                44734542             Pax5                 4                                \-                  \-
  65       Akv wt      SMZL                  4                55369934             Rad23b               1                                \-                  1
  66       Akv-CDH     Plasma cell prolif.   4                57933461             Akap2                0                                1                   \-
  67       Akv-CD      DLBCL (from FBL)      4                97386196             Nfia/D90173          2                                \-                  \-
  68       Akv-EH      DLBCL (from FBL)      4                132220004            Fgr                  3                                \-                  \-
  69       Akv wt      SMZL                  4                134699599            Dscr1l2              0                                1                   \-
  70       Akv-CDH     PCT                   4                138050107            Pla2g2d              0                                1                   \-
  71       Akv wt      FBL                   5                39921672             Hs3st1               0                                1                   \-
  72       Akv-CDH     Lymphoma, NOS         5                65179064             Tlr1                 1                                \-                  1
  73       Akv-CD      Histiocytic sarcoma   5                75074642             \-\--                0                                1                   \-
  74       Akv-CDH     PTLL                  5                107966364            Gfi1                 78                               \-                  \-
  75       Akv-CDH     PCT                   5                121838640            Aldh2                0                                1                   \-
  76       Akv-CDH     DLBCL (from FBL)      5                141077075            Gna12                4                                \-                  \-
  77       Akv wt      DLBCL (from FBL)      6                29717975             4631427C17Rik        0                                1                   \-
  78       Akv-EH      *de novo*DLBCL        6                40821642             BC048599             0                                1                   \-
  79       Akv-CDH     Lymphoma, NOS         6                40955151             2210010C04Rik        0                                1                   \-
  80       Akv-CDH     PCT                   6                54425558             Scrn1                0                                1                   \-
  81       Akv wt      FBL                   6                72441620             BC100525             2                                \-                  \-
  82       Akv wt      PCT                   6                84016089             Dysf                 0                                1                   \-
  83       Akv-CDH     Lymphoma, NOS         6                88923549             Gpr175               0                                1                   \-
  84       Akv-EH      DLBCL (from SMZL)     6                99153396             Foxp1                1                                \-                  1\*
  85       Akv-CDH     Lymphoma, NOS         6                113010477            Thumpd3              1                                \-                  1
  86       Akv-CD      DLBCL (from FBL)      6                120535110            Cecr5                3                                \-                  \-
  87       Akv-CD      Histiocytic sarcoma   6                136905161            Arhgdib              0                                1                   \-
  88       Akv-CD      PCT                   6                145079282            Lrmp                 4                                \-                  \-
  89       Akv-CDH     Plasma cell prolif.   7                18841894             Apoc4                0                                1                   \-
  90       Akv wt      FBL                   7                24263292             Xrcc1                0                                1                   \-
  91       Akv wt      PCT                   7                28498093             5830482F20Rik        0                                1                   \-
  92       Akv-EH      *de novo*DLBCL        7                28691963             Map4k1               1                                \-                  1
  93       Akv-EH      PCT                   7                29760852             Zfp14                0                                1                   \-
  94       Akv-CD      Histiocytic sarcoma   7                30746023             Fxyd5                0                                1                   \-
  95       Akv wt      PCT                   7                45003648             Flt3l                0                                1                   \-
  96       Akv wt      DLBCL (from FBL)      7                66812108             Adamts17             0                                1                   \-
  97       Akv wt      DLBCL (from FBL)      7                73481277             \-\--                7                                \-                  \-
  98       Akv-CD      SMZL                  7                76335733             D430020F16           0                                1                   \-
  99       Akv-EH      DLBCL (from FBL)      7                79083435             Mfge8                0                                1                   \-
  100      Akv-EH      PCT                   7                80764333             AK034740             0                                1                   \-
  101      Akv wt      PCT                   7                82574727             Eftud1               1                                \-                  1\*
  102      Akv-EH      *de novo*DLBCL        7                99422958             Arrb1/mmu-mir-326    0                                1                   \-
  103      Akv wt      SBL                   7                113972740            Rras2/Copb1          32                               \-                  \-
  104      Akv-CDH     DLBCL (from FBL)      7                121248057            AK043969             0                                1                   \-
  105      Akv-EH      *de novo*DLBCL        7                126957227            Cd2bp2               2                                \-                  \-
  106      Akv wt      DLBCL (from FBL)      7                132147451            4631426J05Rik        0                                1                   \-
  107      Akv-CD      DLBCL (from FBL)      7                144741729            Ccnd1                21                               \-                  \-
  108      Akv-CD      SMZL                  8                8401964              \-\--                0                                1                   \-
  109      Akv-EH      DLBCL (from FBL)      8                10980425             \-\--                4                                \-                  \-
  110      Akv wt      FBL                   8                35575516             Dctn6                0                                1                   \-
  111      Akv wt      PCT                   8                37098099             \-\--                0                                1                   \-
  112      Akv-CD      SMZL                  8                74527100             Pgls                 3                                \-                  \-
  113      Akv wt      DLBCL (from FBL)      8                98522228             Gins3                0                                1                   \-
  114      Akv wt      SBL                   8                112753504            BC027816             0                                1                   \-
  115      Akv-EH      *de novo*DLBCL        8                118119184            Wwox                 1                                \-                  1
  116      Akv-EH      Lymphoma, NOS         8                123611854            Irf8                 1                                \-                  \-
  117      Akv-EH      DLBCL (from FBL)      8                126312417            Tubb3/Mela           1                                \-                  1
  118      Akv wt      DLBCL (from FBL)      8                126312418                                                                                      
  119      Akv wt      PCT                   9                46235263             \-\--                0                                1                   \-
  120      Akv-CD      Abscess               9                86514607             A330041J22Rik        0                                1                   \-
  121      Akv-CDH     PCT                   9                104103363            Acpp                 1                                \-                  1
  122      Akv-EH      FBL                   9                115327386            \-\--                0                                1                   \-
  123      Akv wt      PCT                   9                117143474            Rbms3                0                                1                   \-
  124      Akv-EH      PCT                   10               5056902              Syne1                1                                \-                  \-
  125      Akv wt      SBL                   10               7626524              Map3k7ip2            1                                \-                  1
  126      Akv wt      FBL                   10               19681745             Map3k5               2                                \-                  \-
  127      Akv wt      PCT                   10               43100419             Pdss2                0                                1                   \-
  128      Akv-EH      PCT                   10               59295561             Dnajb12              2                                \-                  \-
  129      Akv-CD      Histiocytic sarcoma   10               75678805             Prmt2                0                                1                   \-
  130      Akv wt      FBL                   10               77412375             Pfkl                 0                                1                   \-
  131      Akv wt      DLBCL (from FBL)      10               8009951              BC058238             2                                \-                  \-
  132      Akv wt      DLBCL (from FBL)      10               84366577             Ric8b                0                                1                   \-
  133      Akv-EH      *de novo*DLBCL        10               87574719             BC070476             0                                1                   \-
  134      Akv-EH      *de novo*DLBCL        10               92501677             Pctk2                1                                \-                  \-
  135      Akv-CD      *n.d.*                10               123752010            \-\--                0                                1                   \-
  136      Akv-CDH     PCT                   11               3236433              1500004A08Rik        0                                1                   \-
  137      Akv wt      PCT                   11               5331124              AK133342             0                                1                   \-
  138      Akv wt      DLBCL (from FBL)      11               23587218             4933435A13Rik        4                                \-                  \-
  139      Akv-CD      DLBCL (from FBL)      11               23587651                                                                                       
  140      Akv wt      PCT                   11               32443618             Stk10                1                                \-                  1
  141      Akv wt      PCT                   11               46693128             Timd4                0                                1                   \-
  142      Akv-CD      PCT                   11               51687729             Phf15                0                                1                   \-
  143      Akv-EH      *de novo*DLBCL        11               62648918             Trim16               0                                1                   \-
  144      Akv wt      PCT                   11               67380781             Gas7                 0                                1                   \-
  145      Akv-EH      *de novo*DLBCL        11               74962635             Smg6                 9                                \-                  \-
  146      Akv-EH      *de novo*DLBCL        11               78821537             Ksr1                 0                                1                   \-
  147      Akv-EH      PCT                   11               86862765             Gdpd1                0                                1                   \-
  148      Akv wt      DLBCL (from FBL)      11               95031687             Tac4                 0                                1                   \-
  149      Akv-EH      *de novo*DLBCL        11               102249514            Grn                  0                                1                   \-
  150      Akv wt      DLBCL (from FBL)      11               102990732            Fmnl1                2                                \-                  \-
  151      Akv wt      DLBCL (from FBL)      11               106946907            Nol11                0                                1                   \-
  152      Akv-CD      Abscess               11               107232889            Pitpnc1              1                                \-                  1
  153      Akv-EH      PCT                   11               116126666            Exoc7                0                                1                   \-
  154      Akv-CDH     Lymphoma, NOS         11               118058083            Pscd1                1                                \-                  1\*
  155      Akv-CD      SMZL                  12               3288080              Rab10                0                                1                   \-
  156      Akv wt      PCT                   12               13172238             Ddx1                 0                                1                   \-
  157      Akv-CD      Abscess               12               56600484             Garnl1               0                                1                   \-
  158      Akv-EH      *de novo*DLBCL        12               77286036             Zbtb25               1                                \-                  1
  159      Akv wt      DLBCL (from FBL)      12               80214408             AK132344             1                                \-                  1
  160      Akv wt      DLBCL (from FBL)      12               86569587             Batf                 2                                \-                  \-
  161      Akv-CD      DLBCL (from FBL)      12               113688885            BC004786             5                                \-                  \-
  162      Akv wt      PCT                   13               24453563             Cmah                 1                                \-                  1\*
  163      Akv-CDH     DLBCL (from FBL)      13               28624333             \-\--                0                                1                   \-
  164      Akv wt      PCT                   13               28727388             \-\--                3                                \-                  \-
  165      Akv-CDH     DLBCL (from FBL)      13               28764182                                                                                       
  166      Akv-CDH     DLBCL (from FBL)      13               28950798             Sox4                 79                               \-                  \-
  167      Akv-CD      DLBCL (from FBL)      13               28950905                                                                                       
  168      Akv-EH      *de novo*DLBCL        13               28955972                                                                                       
  169      Akv wt      DLBCL (from FBL)      13               28958981                                                                                       
  170      Akv-EH      DLBCL (from FBL)      13               30695323             Dusp22               4                                \-                  \-
  171      Akv-CD      Histiocytic sarcoma   13               30727958                                                                                       
  172      Akv wt      PCT                   13               31914670             Gmds                 1                                \-                  1
  173      Akv-CD      SMZL                  13               36214883             Fars2                0                                1                   \-
  174      Akv wt      PCT                   13               37804150             Rreb1                8                                \-                  \-
  175      Akv-CD      Histiocytic sarcoma   13               38701503             Eef1e1               1                                \-                  \-
  176      Akv-CD      DLBCL (from FBL)      13               43205444             Gfod1                1                                \-                  1\*
  177      Akv-CD      SMZL                  13               63488458             Fancc                4                                \-                  \-
  178      Akv wt      DLBCL (from FBL)      13               84050271             Mef2c                11                               \-                  \-
  179      Akv-CDH     DLBCL (from FBL)      14               6779744              Dnase1l3             1                                \-                  1
  180      Akv-CDH     Lymphoma, NOS         14               24439077             Rai17                10                               \-                  \-
  181      Akv-CDH     PCT                   14               25348097             Slmap                1                                \-                  1
  182      Akv-EH      Lymphoma, NOS         14               29013598             Cacna1d              0                                1                   \-
  183      Akv wt      SBL                   14               30491074             Btd                  0                                1                   \-
  184      Akv wt      DLBCL (from FBL)      14               59481891             \-\--                0                                1                   \-
  185      Akv wt      FBL                   14               59637396             AK151394             3                                \-                  \-
  186      Akv-EH      *de novo*DLBCL        14               63115780             Msra                 1                                \-                  1\*
  187      Akv wt      PCT                   14               72420139             Sucla2               0                                1                   \-
  188      Akv wt      SMZL                  14               113921088            microRNA cluster     2                                \-                  \-
  189      Akv wt      FBL                   15               57752356             BC066830             0                                1                   \-
  190      Akv-CD      SMZL                  15               58238320             15Ertd621e           0                                1                   \-
  191      Akv wt      PCT                   15               61240727             \-\--                0                                1                   1
  192      Akv wt      PCT                   15               61240729                                                                                       
  193      Akv wt      FBL                   15               73548838             Gpr20/Ptp4a3         6                                \-                  \-
  194      Akv-EH      DLBCL (from FBL)      15               79567673             Unc84b               4                                \-                  \-
  195      Akv wt      DLBCL (from FBL)      15               79728346             Apobec3              0                                1                   \-
  196      Akv-EH      Plasma cell prolif.   15               90445122             Cpne8                1                                \-                  \-
  197      Akv wt      FBL                   16               23906462             Bcl6                 5                                \-                  \-
  198      Akv-EH      *de novo*DLBCL        16               24049008             \-\--                5                                \-                  \-
  199      Akv-CD      DLBCL (from FBL)      16               24086635                                                                                       
  200      Akv-EH      DLBCL (from FBL)      16               24101470                                                                                       
  201      Akv-EH      Lymphoma, NOS         16               24152772                                                                                       
  202      Akv wt      FBL                   16               24178252                                                                                       
  203      Akv wt      DLBCL (from FBL)      16               32049420             Lrrc33               3                                \-                  \-
  204      Akv-CD      *n.d.*                16               52388367             Alcam                1                                \-                  1
  205      Akv wt      PCT                   17               6624877              Vil2                 3                                \-                  \-
  206      Akv wt      PCT                   17               11630998             Park2                1                                \-                  1\*
  207      Akv wt      DLBCL (from FBL)      17               36597927             2410137M14Rik        0                                1                   \-
  208      Akv wt      FBL                   17               49537999             2310015N21Rik        1                                \-                  1\*
  209      Akv-EH      DLBCL (from FBL)      17               63705275             Fert2                0                                1                   \-
  210      Akv-CD      SMZL                  17               71389894             Kntc2                0                                1                   \-
  211      Akv-CDH     PTLL                  17               74614066             Birc6                1                                \-                  \-
  212      Akv wt      PCT                   18               11242422             \-\--                0                                1                   \-
  213      Akv-CD      SMZL                  18               12368360             Npc1                 1                                \-                  1
  214      Akv-CD      SMZL                  18               36016553             Cxxc5                3                                \-                  \-
  215      Akv-CDH     DLBCL (from FBL)      18               39790170             \-\--                0                                1                   \-
  216      Akv wt      FBL                   18               42916219             Ppp2r2b              0                                1                   \-
  217      Akv-EH      *de novo*DLBCL        18               60930595             Ii/Cd74              0                                1                   1
  218      Akv-EH      DLBCL (from FBL)      18               60930793                                                                                       
  219      Akv-CD      DLBCL (from FBL)      18               60930833                                                                                       
  220      Akv wt      PCT                   18               60931233                                                                                       
  221      Akv-CDH     PCT                   18               60934151                                                                                       
  222      Akv wt      DLBCL (from FBL)      18               61103722             Camk2a               0                                1                   \-
  223      Akv-EH      PCT                   18               65601468             Malt1                1                                \-                  \-
  224      Akv wt      DLBCL (from FBL)      18               67824697             Ptpn2                0                                1                   \-
  225      Akv wt      FBL                   19               11607493             Ms4a4d               0                                1                   \-
  226      Akv wt      DLBCL (from FBL)      19               34362400             Fas                  2                                \-                  \-
  227      Akv-EH      *de novo*DLBCL        19               37505125             Hhex/Exoc6           44                               \-                  \-
  228      Akv-CD      DLBCL (from FBL)      19               37532944                                                                                       
  229      Akv-EH      *de novo*DLBCL        19               37537038                                                                                       
  230      Akv-CD      SMZL                  19               37560104                                                                                       
  231      Akv-CD      Histiocytic sarcoma   19               37560104                                                                                       
  232      Akv-EH      PCT                   19               43474871             Cnnm1                0                                1                   \-
  233      Akv-CDH     PCT                   19               47583866             Obfc1                0                                1                   \-
  234      Akv wt      DLBCL (from FBL)      19               47963460             AK014581             0                                1                   \-
  235      Akv wt      PCT                   19               53994934             Shoc2                0                                1                   \-
  236      Akv wt      FBL                   19               55633727             Vti1a                1                                \-                  1\*
  237      Akv wt      FBL                   X                103293531            P2ry10               0                                1                   \-
  238      Akv-CDH     Lymphoma, NOS         X                109985132            Dach2                1                                \-                  1
  239      Akv-EH      DLBCL (from FBL)      X                129928954            Btk                  0                                1                   \-
  240      Akv wt      DLBCL (from FBL)      X                162452646            Tmsb4x               1                                \-                  1

^a^The gene (or RefSeq) closest to the integrated provirus is given (UCSC, mouse mm8 assembly). \-\-- indicates that the distance to the closest gene/RefSeq is more than 100 kb.

^b^For each insertion, it is indicated, based on RTCGD (mm8), whether a novel RIS has been defined.

^c^For each insertion, it is indicated, based on RTCGD (mm8), whether a novel CIS has been defined. The definition follows the recommendations from RTCGD with a window size of 100 kb, 50 kb, and 30 kb for CISs with 4 (or more), 3, or 2 insertions, respectively. \* indicates an exception from this rule, if two integration sites are found within the same gene/RefSeq.

*n.d.*, not determined.

In six cases, the same chromosomal locus was targeted several times. These cases include *Bach2*(hit 4 times), *Sox4*(hit 4 times), *Hhex*(hit 5 times), *Ii*(hit 5 times), a region of chr. 16 not containing any genes/RefSeqs within a distance of 100 kb from the integration sites (hit 5 times), and *LOC433632*(hit 7 times). Five of these integration sites were already registered in RTCGD, only the *Ii*locus define a completely novel RIS/CIS. This latter finding may suggest that *Ii*targeting is strongly associated with the applied model system (virus/mouse strain)\[[@B27]\]. We also note that an integration has taken place within the first intron of *Stk10*in a plasmacytoma induced by Akv-wt (Table [3](#T3){ref-type="table"}, \#140), which appears to be in conflict with the work of Shin *et al.*, 2004 \[[@B28]\] where *Stk10*was described as a SMZL specific candidate gene.

Finally, we examined if specific regions of the targeted gene/RefSeq have been favored with respect to orientation and position of the integrated provirus. We have recently reported of differences between Akv MLV and an enhancer mutant hereof, Akv1-99, in their patterns of proviral insertions around host transcription units in the induced tumors \[[@B29]\]. In line with this, it might be envisioned that destroying the alternative splice sites of the virus could lead to a different pattern of integration site selection during tumorigenesis; *e.g*. it might be speculated if particular positions relative to the target gene somehow would facilitate gene deregulation dependent on the presence or absence of intact SA\' and/or SD\' sites. Accordingly, we allocated each individual integration site position and orientation to a defined region, *i.e.*either upstream, within the promoter, within 1. intron, within last intron, within all other introns, within exons, or downstream of the target gene (Table [4](#T4){ref-type="table"}). Eleven cases in total were excluded as they were positioned -- almost with the same distance -- in between two target genes, upstream of one and downstream of the other. As seen in table [4](#T4){ref-type="table"}, no clear differences with respect to the four viruses were observed, signifying that mutations of the alternative splice sites do not have major effect on the ability of the Akv MLV to affect the target gene/RefSeq from certain positions and/or orientations. It might be worth to notice that the overall picture shows that about half of all integrations are found within introns, and among these there appear to be a tendency for a provirus orientation opposite to that of the target gene. In these cases the formation of chimeric RNA species by promoter insertion and/or splicing would not be predicted.

###### 

Frequency of proviral insertions within defined genomic regions

  **Virus**     **Upstream^a^**               **Promoter^b^**              **1. intron**                **Internal intron**                **Last intron**              **Downstream^c^**               **Exon**              **Outside^d^**
  ------------- ----------------- ----------- ----------------- ---------- --------------- ------------ --------------------- ------------ ----------------- ---------- ------------------- ----------- ---------- ---------- ----------------
  **Akv-wt**    2/104 2%          7/104 7%    5/104 5%          3/104 3%   9/104 9%        16/104 15%   6/104 6%              17/104 16%   2/104 2%          1/104 1%   5/104 5%            8/104 8%    2/104 2%   1/104 1%   11/104 10%
  **Akv-CD**    3/46 7%           6/46 13%    1/46 2%           0/46 0%    3/46 7%         5/46 11%     2/46 4%               8/46 17%     0/46 0%           0/46 0%    4/46 9%             6/46 13%    1/46 2%    0/46 0%    5/46 11%
  **Akv-EH**    3/51 6%           4/51 8%     1/51 2%           0/51 0%    4/51 8%         6/51 12%     2/51 4%               11/51 22%    2/51 4%           0/51 0%    7/51 14%            1/51 2%     2/51 4%    2/51 4%    6/51 12%
  **Akv-CDH**   1/39 3%           2/39 5%     2/39 5%           3/39 8%    7/39 18%        3/39 8%      3/39 8%               5/39 13%     0/39 0%           1/39 3%    5/39 13%            4/39 10%    0/39 0%    0/39 0%    3/39 8%
                                                                                                                                                                                                                              
  **Total**     9/240 4%          19/240 8%   9/240 4%          6/240 3%   23/240 10%      30/240 13%   13/240 5%             41/240 17%   4/240 2%          2/240 1%   21/240 9%           19/240 8%   5/240 2%   3/240 1%   25/240 10%

^a^Within 3--100 kb upstream of target gene/RefSeq

^b^Within 0--3 kb upstream of exon1 of target gene/RefSeq

^c^Within 100 kb downstream of target gene/RefSeq

^d^Proviral integrations \> 100 kb away from gene/RefSeq

\+ or - denotes the orientation of the integrated provirus relative to the target gene/RefSeq.

Discussion
==========

We have in the B-lymphomagenic Akv MLV identified a novel exon, which is defined by the alternative splice acceptor (SA\') and the splice donor (SD\') sites located in the capsid encoding region. While previous studies of Moloney and Friend MLV have demonstrated production of a 4.4 kb transcript using the same SD\' site together with the canonical *env*SA site, this is the first report demonstrating the existence of an alternative SA\' site and production of a double-spliced transcript during the life cycle of a replication-competent simple retrovirus. Yet it remains to be investigated how widespread this competence is. An alignment between six murine retroviruses shows that the conserved splice junction dinucleotide AG is present neither in Cas-Br-E nor in Moloney MLV, although the region in general is well-conserved (Fig. [6](#F6){ref-type="fig"}).

![DNA sequence alignment around the Akv MLV SA\' site in the capsid-coding region of a series of different ecotropic MLVs. The 3\' splice acceptor site consensus sequences are shown on top, with the border of the novel *gag*exon indicated by a vertical line. The boldfaced A in the sequence indicates the presumed branch point.](1742-4690-4-46-6){#F6}

We did not perform detailed analyses of the influence of the splice site mutations on the viral replication. However, since the same number (10^5^to 10^6^) of infectious virus particles, as measured by infectious center assays, were injected from each virus series, and since the mutant viruses induced tumors with comparable incidences and latencies as the wild-type virus, it is not likely that the mutations had imposed severe weakening on the *in vivo*spreading capability. Hence the observed shifts in specificity of the induced tumors most likely are a direct result of the introduced mutations. However, we note that Houzet et al. \[[@B19]\] observed a reduction in titer of SD\'-mutants of Friend virus.

The *in vivo*significance of the alternative splice sites was exposed by a change of the oncogenic properties of Akv MLV, when synonymous mutations destroying the SA\' site, the SD\' site, or both sites simultaneously were introduced. First and foremost, the obvious capability of Akv MLV to induce follicular B cell lymphoma was seriously weakened, when one or both of the alternative splice sites were mutated, suggesting that this competence relies on intact SA\' and SD\' sites and a proper balance between all the produced transcripts (one full-length, two single-spliced, and one double-spliced). The integrity of Akv MLV seems fundamental for its capability to induce FBL; thus we just reported that Akv MLVs with mutated enhancer sequences retained the ability to induce tumors of B-cell type, but altered specificities were observed, including an impaired ability of FBL induction \[[@B11]\]

A more complex picture was observed regarding the strong predisposition of Akv MLV for plasmacytoma induction. This predisposition was affected significantly only if the SA\' alone was mutated. Thus, if the SD\' site was mutated along with SA\', wild-type potential was restored. This may indicate that the ability to induce plasmacytoma is dependent on a fine-tuned balance between the alternative single-spliced and double-spliced transcripts. If no double-spliced transcript is produced, while the single-spliced 4.4 kb transcript still is, as is the case for the SA\' mutant, the single-spliced transcript somehow seems to be related with a barrier for plasmacytoma induction. On the other hand, if both transcripts are produced (Akv-wt) or none of them are produced (the SA\'/SD\' double mutant) the virus will hold a potential for inducing plasmacytomas. This is in line with the overall observation that the most pronounced effects were observed when the SA\' or SD\' splice sites were mutated individually, while the outcome of infection with the SA\'/SD\' double mutant in essence, except for the capability of FBL induction, was comparable to that of the wild-type virus. It may thus be speculated if a delicate balance between the alternatively single-spliced and double-spliced transcripts is a key determinant for the shift in oncogenic specificity, as demonstrated by the SA\' and SD\' splice site Akv mutants.

The most striking shifts in specificity observed were the increased tendency to stimulate development of splenic marginal zone lymphoma and the exposure of a novel ability for inducing histiocytic sarcoma for the SA\' site mutant. Although we have shown that mutation of the SA\' site results in inhibition of generation of the double-spliced product, we are at this point not able to explain or point to any detailed mechanisms underlying the observed changes in specificity. The other remarkable shift in specificity was detected with the SD\' mutant, which was the only virus capable of inducing centroblastic DLBCL, *i.e*. tumors for which an origin from the follicle or marginal zone could not be inferred and comparable to *de novo*DLBCL in humans. Moreover, since the exposed potential appeared quite strong (35% of the SD\'-mutant induced tumors fell within this diagnosis), and since such tumors are in general rare in mice, this mutant virus may be a helpful starting point tool to create a solid mouse model of human *de novo*DLBCL.

Obviously, the proposed significance of proper balances between the four different transcripts for the observed shifts in tumor specificity may reflect a need for a well-regulated balance between resulting translational products. We did not investigate if novel proteins were produced, but the open reading frames (ORFs) of both the alternatively singly and doubly spliced transcripts clearly reveal a potential for additional proteins to be produced. The gene products of the single-spliced 4.4 kb transcript most probably correspond to the p50 and p60 proteins made from the equivalent Friend MLV transcript \[[@B19]\]. These proteins were produced with translation initiations at two initiation codons (AUG^*gag*^and CUG^*glyco*-*gag*^) in the same ORF and were shown to harbor the N-terminal Gag domain including matrix, p12, and the first 110 amino acids of the capsid in frame with the last 116 amino acids of integrase \[[@B19]\]. Also the smaller double-spliced transcript harbors smaller ORFs providing a scene for even more MLV proteins.

Intragenic elements such as *gag*enhancers have been known for many years in avian retroviruses \[[@B30],[@B31]\]. However, it seems unlikely that a similar element is involved here, since the mutant virus with SA\' and SD\' sites mutated together was clearly the less affected one. This observation, in concert with the observed consequence on generation of different splice products, more likely suggests that the effect on disease specificity is related to an RNA processing phenomenon rather than an intragenic *gag*determinant with an effect on transcription.

Lymphoma-induction by non-acute murine retroviruses is associated with multiple proviral insertions that affect critical host genes. To achieve such multiple insertions the superinfection resistance caused by Env-expression must be by-passed. One possibility could be that reduced Env-expression caused by mutation of the *gag*splice sites as reported here might favor superinfection and thereby multiple proviral insertions. While we cannot exclude this possibility, our finding of the same number of sequence tags for proviral insertions for the wild-type and mutated viruses gives no immediately support to such a mechanism.

Retroviral insertional mutagenesis has been established as a solid strategy for the identification of candidate cancer-causing genes \[[@B6],[@B26],[@B32]-[@B34]\]. Accordingly, in an effort to relate specific genes or pathways with specific diagnoses, splice pattern, or causative virus, we identified a pool of 240 integration sites from which 111 novel RISs and 35 novel CISs were defined. Our analyses did not immediately point to any clear correlations; nevertheless the collection of candidate genes may prove to be a central input in future attempts to understand the exact roles of the different splice transcripts and/or their resulting translational products in hematopoietic differentiation and tumorigenesis.

Conclusion
==========

We have in the B-lymphomagenic Akv MLV in the *gag*region identified a novel exon, which represents the first example of a doubly spliced gammaretroviral transcript. Mutations of the alternative splice sites that define this novel transcript change the distribution of the different induced tumor phenotypes as well as generate tumors of additional specificities such as *de novo*diffuse large B cell lymphoma and histiocytic sarcoma. Provirus integration site analyses revealing 111 novel RISs and 35 novel CISs did not clearly point to specific target genes or pathways to be associated with specific tumor diagnoses or individual viral mutants. However, the list of potential target genes will be useful for future studies of hematopoietic differentiation and tumorigenesis.

Methods
=======

Exon trapping
-------------

Exon trapping was performed by using an Exon Trapping System kit (GibcoBRL) in essence according to supplied protocol. In brief, Akv DNA was digested with *Bam*HI or *Bgl*II and all restriction fragments were subcloned into the pSPL3 plasmid, which in addition to sequences necessary for replication and growth in *Escherichia coli*contains SV40 sequences that provide for replication and transcription in COS-7 cells, splicing signals, and a multiple cloning site. Following transformation into *E. coli*, plasmid DNA was isolated and transfected into COS-7 cells. Total RNA was isolated from cultured cells and used for first-strand cDNA synthesis. The cDNA was PCR amplified in two rounds with primers located in the vector exons. The outcome of the PCR amplifications was several different fragments, which were all sequenced. Two of trapped sequences could be verified as exons by RT-PCR analyses of RNA isolated from Akv MLV infected cells. The two trapped exons were defined by the same splice acceptor site (SA\', located in the *gag*region, Fig. [1](#F1){ref-type="fig"}), but by different splice donor sites (SD\' and SD\*, Fig. [1](#F1){ref-type="fig"}), and the sizes were 235 bp and 180 bp, respectively.

Generation of viruses
---------------------

The mutations of Akv MLV at splice acceptor (SA\') and/or splice donor site (SD\') sites were introduced by PCR-based oligonucleotide directed mutagenesis using the following primers harboring the wanted mutations (underlined): Mut-C: 5\'-CTATATAACTGGAAAAATAATAATCC[A]{.ul}TC[A]{.ul}TTC[AG]{.ul}TGA[A]{.ul}GATCCAGGTAAACT-3\', Mut-D: 5\'-GGATTATTATTTTTCCAGTTATATAGATC[GCT]{.ul}GGAGGAAAACG-3\', and Mut-H: 5\'-TTGGGATTACACCACCCAAAG[G]{.ul}GG[AC]{.ul}G[A]{.ul}AACCACCT-3\'. A 720 bp *Bsu*36I -- *Bsu*36I fragment harboring the mutations was cloned into the full length parental provirus. The correct sequence of the introduced *Bsu*36I fragment was verified by sequence analysis.

Pathogenicity experiments
-------------------------

Akv wild-type virus λ623 and the three different alternative splice site mutant viruses, Akv-CD, Akv-EH, and Akv-CDH, mutated in either the SA\' or SD\' site, or in both sites simultaneously, were injected into newborn mice of the inbred NMRI strain, as described in details \[[@B35]\]. Control mice of the same colony were mock injected with 0.1 mL complete medium. The animals were monitored 5 days per week. Mice were sacrificed and autopsied when showing signs of illness or tumor development. Tumor development was diagnosed on the basis of grossly enlarged lymphoid organs after having reached the size described earlier, which is compatible with lymphoma \[[@B36]\]. Lymphoid tumor tissues and the liver were dissected, stored frozen (-80°C) and/or fixed in formalin for further analysis. Statistical analysis was carried out using the two-tailed Fisher\'s exact test.

Histopathological examination and immunohistochemical analysis
--------------------------------------------------------------

Formalin-fixed, paraffin-embedded sections from lymph nodes, thymus, spleen and liver were analyzed. Three-to-five micrometer-thick sections were cut and stained with hematoxylin and eosin (H&E), and when indicated with Giemsa, PAS or chloroacetate esterase. Tumors were classified according to the Bethesda proposals for classification of murine hematopoietic neoplasms \[[@B22],[@B37]\]. Immunohistochemistry was performed on an automated immunostainer (Ventana Medical System, Inc.; AZ, USA), according to the protocol provided by the company with minor modifications. After deparaffinization and rehydration, the slides were placed in a microwave pressure cooker in 0.01 M citrate buffer (pH 6.0), containing 0.1% Tween-20 and heated in a microwave oven at maximum power for 30 min. After cooling in Tris-buffered saline, the sections were incubated with 3% goat or rabbit serum for 20 min. The antibody panel used included CD3, CD79acy, TdT, myeloperoxidase (Dako, Hamburg, Germany), B220/CD45R and MAC3 (BD Pharmingen, NJ, USA). Appropriate positive controls were used to confirm the adequacy of the staining.

Northern blot analysis
----------------------

Total cellular RNA was extracted from chronically infected NIH 3T3 cells by Trizol Reagent (Invitrogen), following the manufacturer\'s recommendations. Approximately 25 μg of RNA from each series (Akv-wt, Akv-CD, Akv-EH, Akv-CDH, and mock-infected cells) was size-fractionated on a 1.2% formaldehyde/agarose gel, and transferred to a nylon filter membrane (Zeta-Probe GT; Bio-Rad) under alkaline conditions (50 mM NaOH). Prehybridzation, hybridization, and washing procedures were according to standard protocol described in the instruction manual from Zeta-Probe GT \[(pre)hybridization buffer: 0.25 M sodium phosphate, pH 7.2, 7% SDS, and washing buffers: 20 mM sodium phosphate, ph 7.2, 5% (1%) SDS). The hybridization probes were a ^32^P random priming labeled envelope specific probe (a 330 bp *Sma*I fragment of Akv MLV (positions 6240to 6570) \[[@B38]\]\]) and a ^32^P random priming labeled *gag*specific probe covering the novel exon. The *gag*probe was a 380 bp PCR-fragment amplified by the following primers: *gag*-forward: 5\'-ATGGTCAGTTGCAGTACTGGCCGT-3\' and *gag*-reverse: 5\'-TGGGGCTTCGGCCCGCGTTTTGGA-3\'. The integrity and concentration of the RNA were confirmed by visual inspection of ethidium bromide-stained 18S and 28S rRNAs.

PCR and RT-PCR analyses
-----------------------

Genomic DNA was purified from frozen tumor tissues by DNeasy Tissue Kit (Qiagen). Conservation of the introduced mutations was examined by PCR amplifying the region enclosing the mutations and by using the primers depicted in Fig. [1](#F1){ref-type="fig"} (primer sequences and positions in Akv provirus: Forward primer, 5\'-CCTATGAACCCCCTCCGTGGGTCA-3\', nucleotides 1387--1410, and Reverse primer, 5\'-TATTAAAGATCCTTTCGGCTTC-3\', nucleotides 2412--2390). The resulting PCR products were analyzed by agarose gel electrophoresis, purified, and sequenced with nested sequencing primers (numberings refer to positions in Akv provirus). Forward primer, 5\'-CGGGGAGGAGAAGCAGCGGGTGCT-3\', nucleotides 1952--1976, and Reverse primer, 5\'-GTCCCTAATAATTGCTGGCAAT-3\', nucleotides 1942-1921.

For the RT-PCR analyses, total cellular RNA was extracted from tumor tissues or chronically infected NIH 3T3 cells by Trizol Reagent (Invitrogen), following the manufacturer\'s recommendations. 1--5 μg total RNA was used to make first-strand cDNA by First-Strand cDNA Synthesis Kit (Amersham Biosciences) with an oligo-dT primer. This was followed by standard PCR amplification using four different primer sets, \#1 to \#4. Primer set \#1: Forward primer, 5\'-CCGACCCACCGTCGGGAGGAT-3\', and reverse primer, 5\'-CCTCATCAAACAGGGTGGGACT-3\'. Primer set \#2: Forward primer, 5\'-CCGACCCACCGTCGGGAGGAT-3\', and reverse primer, 5\'-CACCCACACGGAGTCTCCAAT-3\'. Primer set \#3: Forward primer, 5\'-GATTACACCACCCAAAGAGCTC-3\', and reverse primer, 5\'-CACCCACACGGAGTCTCCAAT-3\'. Primer set \#4 (*env*transcript): Forward primer, 5\'-TTGGAGACCCCCGCCCAGGGACCACC-3\', and reverse primer, 5\'-CACCCACACGGAGTCTCCAAT-3\'. The resulting RT-PCR products were analyzed by agarose gel electrophoresis, and in most cases purified and sequenced.

Provirus tagging and analyses
-----------------------------

Genomic DNA isolated from the induced tumors was analyzed for provirus integration sites by a splinkerette-based PCR method \[[@B26]\], described in details in \[[@B39]\]. The resulting host/virus junction fragments were sequenced, and the cellular flanking sequences were compared (BLAT search) to the UCSC Genome Browser, version mm8, to determine the chromosomal position of the integrated provirus. To identify possible novel retrovirus integration sites (RISs) and common integration sites (CISs), the individual integration sites were concomitantly matched up to the Retroviral Tagged Cancer Gene Database (RTCGD), version mm8 \[[@B24],[@B25]\]. The definition of a CIS follows the recommendations from RTCGD with a window size of 100 kb, 50 kb, and 30 kb for CISs with 4 (or more), 3, or 2 insertions, respectively. Exception from the recommended window sizes was allowed in a few cases when two (or more) integrations were found within the same gene/RefSeq (Table [3](#T3){ref-type="table"}).

DNA sequencing analysis
-----------------------

Amplified PCR products or purified plasmid preparations were sequenced with the DYEnamic ET terminator cycle sequencing kit (Amersham Pharmacia Biotech), following the manufacturer\'s recommendations, and reaction products were analyzed on an automated DNA sequencer (Applied Biosystems Inc.).
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